An observational study in Multiple Sclerosis, sponsored by Afyonkarahisar Health Sciences University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Afyonkarahisar Health Sciences University · Observational
Among 307 studies in Multiple Sclerosis with a site in Turkey — 59 open to participants now, 78 under way, 10 of them phase 3. Multiple Sclerosis · Turkey.
Among the 307 studies in Multiple Sclerosis with a site in Turkey, this one is the 90th largest by planned enrollment of the 103 observational ones that give a count, is one of 43 that started in 2026, is one of 103 observational ones, reaches primary completion later than 46 of the 77 other live ones, and was the 293rd registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 307 studies in Multiple Sclerosis with a site in Turkey are open now. Recruiting first, the newest first:
Yuzuncu Yil University · Sites in Turkey
Ages 18–65
Suleyman Demirel University · Sites in Turkey
Ages 18–65
Hacettepe University · Sites in Turkey
Ages 18–65
Kutahya Health Sciences University · Sites in Turkey
Ages 18+
Büşra Seçkinoğulları Korkusuz · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 43 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 40 across the 204 interventional studies, 60 across the 103 observational. Of the 204 that completed or were terminated, 37 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 307 have an industry lead sponsor. The 10 most frequent:
Afyonkarahisar Health Sciences University is the lead sponsor of 115 studies on the registry; 32 are open to participants now.
Afyonkarahisar Health Sciences University has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07137624Hacettepe UniversityMotor Imagery and Action Observation for Gait Function in MS | 2026-11 |
| NCT07571304Istanbul University - CerrahpasaDual-Task Training in Pediatric Multiple Sclerosis | 2026-12-01 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06777134Berivan Beril KılıçRelationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients | 2026-12-10 |
Add all 17 to your calendar (.ics) → With an account.
Among the 307 studies in Multiple Sclerosis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional observational study aims to investigate the relationship between obstacle crossing performance under single-task and dual-task conditions and the levels of fatigue and disability in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS). Walking performance will be assessed under standard walking and obstacle crossing conditions with and without a concurrent cognitive task. The study will examine how increased task complexity affects walking performance and its association with fatigue, disability, cognition, and functional mobility.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that frequently causes gait impairment, fatigue, cognitive dysfunction, and reduced functional mobility. Since daily activities often require simultaneous motor and cognitive performance, assessment under dual-task conditions provides clinically meaningful information beyond conventional gait evaluation.
Obstacle crossing represents a more demanding walking task than level walking and may better reflect mobility challenges encountered in everyday life. Although dual-task walking has been investigated in individuals with MS, studies examining obstacle crossing performance under both single-task and dual-task conditions and its relationship with fatigue and disability remain limited.
This cross-sectional observational study will include men and women aged 18 to 65 years with Relapsing-Remitting Multiple Sclerosis who are followed at the Neurology Outpatient Clinic of Kocaeli City Hospital. Participants will complete walking assessments under four conditions: single-task walking, dual-task walking, single-task obstacle crossing, and dual-task obstacle crossing. The dual-task condition will require participants to perform serial-3 subtraction while walking.
Clinical assessments including fatigue, walking limitation, cognition, health-related quality of life, and fear of movement will also be collected. The study aims to determine the association between obstacle crossing performance and fatigue and disability levels in individuals with RRMS.
Adults aged 18 to 65 years with Relapsing-Remitting Multiple Sclerosis who are followed at the Neurology Outpatient Clinic of Kocaeli City Hospital, have an EDSS score between 0 and 6, are clinically stable, and meet all eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 to 65 years with a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) according to the 2017 McDonald criteria, an Expanded Disability Status Scale (EDSS) score between 0 and 6, a Montreal Cognitive Assessment (MoCA) score of 26 or higher, and a clinically stable disease course during the previous 6 months. Participants will undergo observational assessments of walking, obstacle crossing performance, fatigue, cognition, functional mobility, and fear of movement. No intervention will be administered.
Dual-Task Cost During Obstacle Crossing
Walking performance will be assessed using the 10-Meter Walk Test under four conditions: single-task walking, dual-task walking with serial-3 subtraction, single-task obstacle crossing, and dual-task obstacle crossing with serial-3 subtraction. Walking time and cognitive task performance will be recorded. Dual-Task Cost (DTC, %) will be calculated to quantify the effect of performing a concurrent cognitive task during walking.
Time frame: Baseline
The Modified Fatigue Impact Scale (MFIS)
The Modified Fatigue Impact Scale (MFIS) evaluates the impact of fatigue on physical, cognitive, and psychosocial functioning during the previous month. Total scores range from 0 to 84, with higher scores indicating greater fatigue impact
Time frame: Baseline
Multiple Sclerosis Walking Scale-12 (MSWS-12)
The Multiple Sclerosis Walking Scale-12 is a patient-reported outcome measure that evaluates the impact of multiple sclerosis on walking ability. Raw total scores range from 12 to 60, with higher scores indicating greater walking limitation.
Time frame: Baseline
Monitoring My Multiple Sclerosis Scale (MMMS)
The Monitoring My Multiple Sclerosis Scale (MMMS) evaluates physical status, relationships, energy, and cognitive or mental status. Total scores range from 26 to 104, with higher scores indicating better health status and functioning.
Time frame: Baseline
Tampa Scale for Kinesiophobia (TSK)
The Tampa Scale for Kinesiophobia (TSK) is a 17-item questionnaire used to assess fear of movement. Total scores range from 17 to 68, with higher scores indicating greater kinesiophobia.
Time frame: Baseline
Fatigue Severity Scale (FSS)
The Fatigue Severity Scale (FSS) assesses the severity of fatigue and its impact on daily functioning. It consists of 9 items scored from 1 to 7. The total score is calculated as the mean of the 9 items, ranging from 1 to 7, with higher scores indicating greater fatigue severity.
Time frame: Baseline
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Afyonkarahisar Health Sciences University →